Compare SOTK & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | IMUX |
|---|---|---|
| Founded | 1975 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 75.2M |
| IPO Year | 1995 | 2013 |
| Metric | SOTK | IMUX |
|---|---|---|
| Price | $4.08 | $1.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 29.0K | ★ 4.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $20,504,381.00 | N/A |
| Revenue This Year | $4.02 | N/A |
| Revenue Next Year | $10.95 | N/A |
| P/E Ratio | $53.00 | ★ N/A |
| Revenue Growth | ★ 4.08 | N/A |
| 52 Week Low | $3.23 | $0.51 |
| 52 Week High | $5.15 | $1.35 |
| Indicator | SOTK | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 45.07 | 76.19 |
| Support Level | $4.03 | $0.61 |
| Resistance Level | $4.32 | N/A |
| Average True Range (ATR) | 0.23 | 0.12 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 8.78 | 95.79 |
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.